Neumora Therapeutics, Inc.
NMRA
$1.20
-$0.05-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.91M | 14.27M | 13.81M | 12.18M | 15.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.19M | 52.86M | 58.48M | 52.70M | 54.04M |
| Operating Income | -42.19M | -52.86M | -58.48M | -52.70M | -54.04M |
| Income Before Tax | -43.08M | -53.43M | -59.45M | -56.76M | -52.71M |
| Income Tax Expenses | -- | 30.00K | 0.00 | -- | 25.00K |
| Earnings from Continuing Operations | -43.08M | -53.46M | -59.45M | -56.76M | -52.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.08M | -53.46M | -59.45M | -56.76M | -52.73M |
| EBIT | -42.19M | -52.86M | -58.48M | -52.70M | -54.04M |
| EBITDA | -42.18M | -52.86M | -58.47M | -52.68M | -54.02M |
| EPS Basic | -0.23 | -0.30 | -0.35 | -0.35 | -0.33 |
| Normalized Basic EPS | -0.15 | -0.19 | -0.22 | -0.20 | -0.20 |
| EPS Diluted | -0.23 | -0.30 | -0.35 | -0.35 | -0.33 |
| Normalized Diluted EPS | -0.15 | -0.19 | -0.22 | -0.20 | -0.20 |
| Average Basic Shares Outstanding | 185.16M | 179.87M | 168.52M | 161.84M | 161.69M |
| Average Diluted Shares Outstanding | 185.16M | 179.87M | 168.52M | 161.84M | 161.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |